RecruitingNot ApplicableNCT05057702

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

A Pilot Feasibility and Efficacy (Phase 2) Trial of Real Time Drug Screening and Genomic Testing to Determine an Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma


Sponsor

University of California, San Francisco

Enrollment

74 participants

Start Date

Feb 22, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in the pilot phase of performing real-time drug screening on tissue taken during surgery in patients with relapsed medulloblastoma or ependymoma and of having a specialized tumor board assign a treatment plan based on the results of this screening and genomic sequencing. The aim of this trial is to allow every child and young adult with relapsed medulloblastoma and ependymoma to receive the most effective and least toxic therapies currently available and will pave the way for improved understanding and treatment of these tumors in the future. Moreover, if successful, it could serve as a paradigm for personalized medicine programs for other types of cancer.


Eligibility

Min Age: 12 MonthsMax Age: 39 Years

Plain Language Summary

Simplified for easier understanding

This study creates individualized treatment plans for children and young adults whose brain tumors — specifically medulloblastoma or ependymoma — have come back after initial treatment. The team analyzes the tumor tissue from a new surgery to guide personalized therapy. **You may be eligible if...** - You have recurrent (returned) medulloblastoma or ependymoma — either your first or second relapse - Your tumor can be accessed surgically and enough tissue can be collected - You have recovered from prior chemotherapy, radiation, or surgery **You may NOT be eligible if...** - Your tumor cannot be safely reached by surgery - You have not yet fully recovered from previous cancer treatments - You received certain treatments too recently (e.g., chemotherapy within 7 days, antibody therapy within 21 days) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERSpecialized Tumor Board Treatment Plan

Specialized Treatment Plan of up to four FDA approved drugs based on participant's screening results will be assigned by PNOC specialized tumor board

OTHERCombinations

Specialized Treatment Plan of up to four FDA approved drugs based on participant's screening results will be assigned by PNOC specialized tumor board


Locations(8)

Children's Hospital of Los Angeles

Los Angeles, California, United States

Rady Children's Hospital

San Diego, California, United States

University of California, San Francisco

San Francisco, California, United States

Children's National Hospital

Washington D.C., District of Columbia, United States

St. Louis Children's Hospital / Washington University in St. Louis

St Louis, Missouri, United States

New York University

New York, New York, United States

Columbia University Medical Center

New York, New York, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05057702


Related Trials